Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
Psychedelics Psilocybin safer to take with psychiatric medications than MDMA, researchers say Mixing MDMA with heavier antidepressants can be fatal Natalia Buendia CalvilloMarch 10, 2022
Business Numinus approved to study ayahuasca and San Pedro in Canada Used in sacred traditions for centuries, the firm says research will bring their medicinal benefits to a larger audience Natalia Buendia CalvilloMarch 9, 2022
News Only difference between LSD and synthetic psilocybin experience is duration, researchers say But there are some physiological differences between the two Natalia Buendia CalvilloMarch 2, 2022
News Psilocybin therapy for major depression can relieve symptoms for a year: study The long-term benefits contrast with the more temporary effects of conventional antidepressants Natalia Buendia CalvilloFebruary 18, 2022
Canada Canadian health professionals are limited to clinical trials to access psilocybin. Experts say that’s unethical Health Canada's guidance on how to access illicit substances for medical purposes has been a moving target over the past year Natalia Buendia CalvilloFebruary 16, 2022
Canada Vancouver Island University to launch Canada’s first psychedelic-assisted therapy graduate program 'Psychedelic-assisted therapy will be an integral part of mental wellness therapeutic models in the very near future,' says one of the program's coordinators Natalia Buendia CalvilloFebruary 14, 2022
Canada Canadian advocates denounce ‘flawed’ system for legal psilocybin access It appeared Health Canada was increasing access to the substance, but recent events suggest otherwise Natalia Buendia CalvilloFebruary 3, 2022
Business Numinus uplists to OTCQX Best Market Stock will start trading at market open Thursday under the symbol NUMIF Natalia Buendia CalvilloJanuary 26, 2022
Business Numinus ups revenue 61% thanks to psychedelic-focused therapy programs Expenses were down 71% but the firm still reported a $5.4-million loss Natalia Buendia CalvilloJanuary 21, 2022